The significance of tumour markers as an indication for mediastinoscopy in non-small cell lung cancer

被引:19
|
作者
Ando, S
Kimura, H
Iwai, N
Kakizawa, K
Shima, M
Ando, M
机构
[1] Chiba Canc Ctr, Div Thorac Dis, Chuoh Ku, Chiba 2608717, Japan
[2] Chiba Univ, Sch Med, Dept Chest Med, Chiba 280, Japan
[3] Chiba Univ, Sch Med, Dept Publ Hlth, Chiba 280, Japan
关键词
mediastinoscopy; non-small cell lung cancer; tumour markers;
D O I
10.1046/j.1440-1843.2003.00443.x
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Objective: The purpose of this study was to verify the significance of tumour markers as indicators for mediastinoscopy in non-small cell lung cancer. Methodology: In the past 4 years, 205 patients with non-small cell lung carcinoma (NSCLC) underwent surgical resection at Chiba Cancer Center, Chiba, Japan. The correlation between the serum levels of eight tumour markers (CEA, AFP, CA19-9, SCC, NSE, CA125, CYFRA, ProGRP) and the presence of N2 disease was analysed. Univariate and multivariate analyses were performed to determine the relationship between both marker levels and clinical findings and N2 disease. Results: In multivariate analysis, positive CEA was significantly associated with the diagnosis of N2 disease. We also demonstrated that when CA125, CYFRA and ProGRP were positive, they were individually significantly associated with N2 disease. However, CEA was superior to the other markers and equivalent to a combination of various tumour markers. Conclusion: It was concluded that evaluation of CEA in addition to CT is of use in the diagnosis of N2 disease in NSCLC patients and should be used as an indication for mediastinoscopy.
引用
收藏
页码:163 / 167
页数:5
相关论文
共 50 条
  • [1] Clinical significance of disseminated tumour cells in non-small cell lung cancer
    Rud, A. K.
    Borgen, E.
    Maelandsmo, G. M.
    Flatmark, K.
    Le, H.
    Josefsen, D.
    Solvoll, I.
    Schirmer, C. B.
    Helland, A.
    Jorgensen, L.
    Brustugun, O. T.
    Fodstad, O.
    Boye, K.
    [J]. BRITISH JOURNAL OF CANCER, 2013, 109 (05) : 1264 - 1270
  • [2] Approved indication: non-small cell lung cancer
    不详
    [J]. AUSTRALIAN PRESCRIBER, 2020, 43 (06) : 216 - 217
  • [3] Prognostic significance of immunohistochemical markers in non-small cell lung cancer.
    Renouf, D.
    Wood-Baker, R.
    Ionescu, D.
    Leung, S.
    Massoudi, H.
    Gilks, B.
    Laskin, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 416S - 416S
  • [4] Repeat mediastinoscopy after neoadjuvant therapy for non-small cell lung cancer
    Maas, KW
    Schramel, FMNH
    [J]. LUNG CANCER, 2003, 39 (03) : 347 - 347
  • [5] Mediastinoscopy for Staging of Non-Small Cell Lung Cancer: Surgical Performance in The Netherlands
    Hoeijmakers, Fieke
    Heineman, David J.
    Beck, Naomi
    Klamer, Jolien
    Tollenaar, Rob A. E. M.
    Wouters, Michel W. J. M.
    Schreurs, Wilhelmina H.
    [J]. ANNALS OF THORACIC SURGERY, 2019, 107 (04): : 1024 - 1031
  • [6] The role of endobronchial ultrasound versus mediastinoscopy for non-small cell lung cancer
    Czarnecka-Kujawa, Katarzyna
    Yasufuku, Kazuhiro
    [J]. JOURNAL OF THORACIC DISEASE, 2017, 9 : S83 - S97
  • [7] THE CLINICAL VALUE OF MEDIASTINOSCOPY IN PREOPERATIVE STAGING OF NON-SMALL CELL LUNG CANCER
    Kim, D.
    Jin, H. Seok
    Hyochae, P.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S66 - S66
  • [8] Safety and Utility of Mediastinoscopy in Non-Small Cell Lung Cancer in a Complex Mediastinum
    Louie, Brian E.
    Kapur, Seema
    Farivar, Alexander S.
    Youssef, Samuel J.
    Gorden, Jed
    Aye, Ralph W.
    Vallieres, Eric
    [J]. ANNALS OF THORACIC SURGERY, 2011, 92 (01): : 278 - 283
  • [9] Mediastinoscopy in patients with clinical stage I non-small cell lung cancer
    Choi, YS
    Shim, YM
    Kim, J
    Kim, K
    [J]. ANNALS OF THORACIC SURGERY, 2003, 75 (02): : 364 - 366
  • [10] Heterogeneity of immunostaining for tumour markers in non-small cell lung carcinoma
    Macdonald, C
    Michael, A
    Colston, K
    Mansi, J
    [J]. EUROPEAN JOURNAL OF CANCER, 2004, 40 (03) : 461 - 466